FDA approves BeiGene's Brukinsa in rare blood cancer

seekingalpha2021-09-02

BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). WM is a type of cancer affecting two...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Nichktan
2021-09-02
Nichktan
Like and comment pls
- Moneyong:
  Ok
Sriwonc
2021-09-02
Sriwonc
Like pls
- Nichktan:
  Like and Comment pls
Jen88
2021-09-02
Jen88
Good
- Kelvinneo:
  okay
Heidit
2021-09-02
Heidit
Cool
- Jen88:
  Liked
alexcsb
2021-09-02
alexcsb
Biotech nowadays getting popular
- cHao7:
  huat
LIM97
2021-09-02
LIM97
like n comment
- Heidit:
  Ok
- Demong:
  Ok

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127321282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-02 16:39","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1127321282","market":"us","top_or_hot":-1,"title":"FDA approves BeiGene's Brukinsa in rare blood cancer","media":"seekingalpha","content":"<div>\n<p>BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two...</p>\n\n<a href=\"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves BeiGene's Brukinsa in rare blood cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves BeiGene's Brukinsa in rare blood cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two...</p>\n\n<a href=\"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"https://seekingalpha.com/news/3736525-fda-approves-beigenes-brukinsa-in-rare-blood-cancer","article_id":"1127321282","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127321282","pubTimestamp":1630571951,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatme","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BGNE":"百济神州"},"translate_title":"FDA批准百济神州Brukinsa用于罕见血癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":0.9},"content_text":"BeiGene(NASDAQ:BGNE)announces that BRUKINSA (zanubrutinib) has received FDA approval for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).\nWM is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. Both cell types are white blood cells.\nThe approval is primarily based on efficacy results from the Phase 3 ASPEN trial comparing BRUKINSA to ibrutinib in patients with WM.\n“We are delighted by today’s FDA approval for BRUKINSA in its second indication, offering a new treatment option with demonstrated efficacy and safety benefits for patients with Waldenström’s macroglobulinemia,\" commented Jane Huang, M.D., Chief Medical Officer, Hematology at BeiGene.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":812860138,"gmtCreate":1630573938424,"gmtModify":1676530344351,"author":{"id":"3567067978989911","authorId":"3567067978989911","name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3567067978989911","authorIdStr":"3567067978989911"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812860138","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729109,"gmtCreate":1630574851539,"gmtModify":1663233277847,"authorId":3575367895713518,"author":{"id":3575367895713518,"idStr":"3575367895713518","authorId":3575367895713518,"name":"Moneyong","avatar":"https://static.tigerbbs.com/310106f7833de54751b1a4f33ac43e61","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.96%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812860138,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":812884872,"gmtCreate":1630573700996,"gmtModify":1676530344310,"author":{"id":"3586424409701165","authorId":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"idStr":"3586424409701165","authorIdStr":"3586424409701165"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812884872","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729019,"gmtCreate":1630573954893,"gmtModify":1663233280126,"authorId":3567067978989911,"author":{"id":3567067978989911,"idStr":"3567067978989911","authorId":3567067978989911,"name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812884872,"type":1,"supId":0,"prevId":0,"content":"Like and Comment pls","text":"Like and Comment pls","html":"Like and Comment pls"}],"langContent":"EN"},{"id":812814225,"gmtCreate":1630572797667,"gmtModify":1676530344098,"author":{"id":"3582993517958198","authorId":"3582993517958198","name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582993517958198","authorIdStr":"3582993517958198"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812814225","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728901,"gmtCreate":1630573151673,"gmtModify":1631889828884,"authorId":3576527829922352,"author":{"id":3576527829922352,"idStr":"3576527829922352","authorId":3576527829922352,"name":"Kelvinneo","avatar":"https://static.tigerbbs.com/02f9dc9fba8b950702638da01ab252b8","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.14","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812814225,"type":1,"supId":0,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"}],"langContent":"EN"},{"id":812812573,"gmtCreate":1630572667892,"gmtModify":1676530344052,"author":{"id":"3585567341976837","authorId":"3585567341976837","name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585567341976837","authorIdStr":"3585567341976837"},"htmlText":"&nbsp;Cool&nbsp;","listText":"&nbsp;Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812812573","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728852,"gmtCreate":1630572803902,"gmtModify":1663233276558,"authorId":3582993517958198,"author":{"id":3582993517958198,"idStr":"3582993517958198","authorId":3582993517958198,"name":"Jen88","avatar":"https://static.tigerbbs.com/5aaf732b230f1241c2c9b76b2b27ae00","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812812573,"type":1,"supId":0,"prevId":0,"content":"Liked","text":"Liked","html":"Liked"}],"langContent":"EN"},{"id":812818927,"gmtCreate":1630572468569,"gmtModify":1676530343989,"author":{"id":"3586915072418371","authorId":"3586915072418371","name":"alexcsb","avatar":"https://static.tigerbbs.com/b02b98b9a53bdc70b2b8955a1bb7db4f","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3586915072418371","authorIdStr":"3586915072418371"},"htmlText":"Biotech nowadays getting popular&nbsp;","listText":"Biotech nowadays getting popular&nbsp;","text":"Biotech nowadays getting popular","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812818927","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728863,"gmtCreate":1630572853529,"gmtModify":1663233277042,"authorId":3571630433284403,"author":{"id":3571630433284403,"idStr":"3571630433284403","authorId":3571630433284403,"name":"cHao7","avatar":"https://static.tigerbbs.com/3800b5d66328f3184368a219227b02a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812818927,"type":1,"supId":0,"prevId":0,"content":"<u>huat</u>","text":"<u>huat</u>","html":"<u>huat</u>"}],"langContent":"EN"},{"id":812811549,"gmtCreate":1630572433581,"gmtModify":1676530343973,"author":{"id":"3581419265926610","authorId":"3581419265926610","name":"LIM97","avatar":"https://static.tigerbbs.com/6e8b924a13e75ddd5dcb294949bced1f","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581419265926610","authorIdStr":"3581419265926610"},"htmlText":"like n comment","listText":"like n comment","text":"like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/812811549","repostId":1127321282,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728825,"gmtCreate":1630572662778,"gmtModify":1663233277938,"authorId":3585567341976837,"author":{"id":3585567341976837,"idStr":"3585567341976837","authorId":3585567341976837,"name":"Heidit","avatar":"https://static.tigerbbs.com/b15a14bcb1e7c71684448d84f3e500e7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812811549,"type":1,"supId":0,"prevId":0,"content":"Ok ","text":"Ok ","html":"Ok "},{"id":5728835,"gmtCreate":1630572730632,"gmtModify":1663233277527,"authorId":3581632751482150,"author":{"id":3581632751482150,"idStr":"3581632751482150","authorId":3581632751482150,"name":"Demong","avatar":"https://static.tigerbbs.com/dbceb89832d6c8630b4f99a879c4878d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812811549,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":44,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127321282"}